1 Stock Under $50 to Target This Week and 2 We Ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
YahooyesterdayBSX
2 Reasons to Watch BSX and 1 to Stay Cautious
Boston Scientific has gotten torched over the last six months - since March 2026, its stock price has dropped 36.9% to $48.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Yahoo2 days agoBSX
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?
Despite Boston Scientific’s weak performance relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects
Yahoo2 days agoBSX
The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.
Yahoo3 days agoBSX
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo7 days agoBSX
Are You Still Holding Boston Scientific Stock For Its Next Device?
Its capital budget has overtaken its research budget for the first time in the fifteen years on record, and two of the seven launches management is counting on to restore growth come from outside its own labs.
Yahoo14 days agoBSX
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga14 days agoBSX
Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises
Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]
Yahoo17 days agoBSX
If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today
Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.54% on an annualized basis producing an average annual return of 15.01%. Currently, Boston Scientific has a market capitalization of
Benzinga18 days agoBSX
Boston Scientific (BSX), What Is Behind The Latest Investor Attention?
Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...
Yahoo20 days agoBSX
Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?
In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish...
Yahoo20 days agoBSX
Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?
Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...
Yahoo20 days agoBSX
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
Yahoo21 days agoBSX
Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500’s 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as […]
Yahoo21 days agoBSX